20 Dec 2024 - 20 Dec 2025

09:00 AM - 09:00 PM

8th annual year ended review in lung cancer 2024

Program Director: Undiscolosed

8th annual year-end review in lung cancer 2024. Date: 20 Dec 2024

Day 1 Sessions

Date : 20 Dec 2024

ESMO 1538O Environmental pollutants and molecular alterations in non-small cell lung cancer: Insights from the KBP-2020 cohort study 09:30 AM - 09:40 AM
Non-invasive diagnosis of pulmonary nodules by circulating tumor DNA methylation: A prospective multicenter study 09:40 AM - 09:47 AM
Prevalence of pathogenic or likely pathogenic germline variants in cancer predisposition genes among selected patients with lung adenocarcinoma: The GERMLUNG study 09:47 AM - 09:54 AM
Sublobar Resection vs Lobectomy for High-Risk Stage I Non–Small Cell Lung Carcinoma 09:54 AM - 10:01 AM
Stereotactic vs Hypofractionated Radiotherapy for Inoperable Stage I Non-Small Cell Lung Cancer: The LUSTRE Phase 3 Randomized Clinical Trial. 10:01 AM - 10:08 AM
MA03.03 The Impact of AI-driven 3D Reconstruction on Pulmonary Surgery Planning (AIR-SURGE): A Multi-Center Multi-Reader Multi-Case Study (WCLC 2024) 10:08 AM - 10:15 AM
MA03.07 Outcomes of Older Patients in CALGB 140503 (Alliance): Lobar vs Sublobar Resection for Peripheral Stage IA Non-Small Cell Lung Cancer [WCLC 2024] 10:15 AM - 10:22 AM
Integrating IO in management of early lung-in both operative and inoperative setting. 10:22 AM - 10:52 AM
Neoadjuvant pembrolizumab plus chemotherapy followed by adjuvant pembrolizumab compared with neoadjuvant chemotherapy alone in patients with early-stage non-small-cell lung cancer (KEYNOTE-671) 11:22 AM - 11:32 AM
NEOTORCH Trial: Perioperative Toripalimab + Chemo in Resectable NSCLC – Phase 3 Results. 11:32 AM - 11:39 AM
RATIONALE-315: Neoadjuvant Tislelizumab + Chemo in Resectable NSCLC – ESMO 2024 Results 11:39 AM - 11:46 AM
AEGEAN Trial: Perioperative Durvalumab & ctDNA Clearance in Resectable NSCLC 11:46 AM - 11:56 AM
NADIM Trial: 5-Year Outcomes of Perioperative Nivolumab + Chemo in Stage III NSCLC 11:56 AM - 12:03 PM
ALNEO Trial: Neoadjuvant Alectinib in Resectable Stage III ALK+ NSCLC – WCLC 2024 Interim Data. 12:10 PM - 12:17 PM
ADAURA Trial: MRD Analysis of Adjuvant Osimertinib in Resected EGFR-Mutated NSCLC – ASCO 2024 12:17 PM - 12:24 PM
Combining Local & Systemic Therapy in NSCLC: Perioperative, Neoadjuvant & Adjuvant Strategies 12:24 PM - 01:00 AM
Breakthrough in Stage III NSCLC: NRG-RTOG 1106 Adaptive Radiotherapy Trial Results (JCO 2024) 02:00 AM - 02:07 AM
SEISMIC Trial Results: Endoscopic Mediastinal Staging to Guide Radiotherapy in NSCLC 02:07 AM - 02:14 AM
NRG LU008 Trial: SBRT + Chemoradiation for Locally Advanced NSCLC | Phase III Results (JTO) 02:14 AM - 02:21 AM
ESMO 2024: Beclomethasone Inhalation with Radiotherapy in LA-NSCLC | 1242MO Phase II Trial 02:21 AM - 02:28 AM
LAURA Trial (NEJM/ASCO 2024): Osimertinib After Chemoradiotherapy in Stage III EGFR+ NSCLC 02:08 AM - 02:35 AM
POLESTAR Trial (WCLC 2024): Aumolertinib After Chemoradiotherapy in Stage III EGFR+ NSCLC 02:35 AM - 02:42 AM
PACIFIC-2 Final Results | Durvalumab + Chemoradiotherapy in Stage III NSCLC | ELCC 2024 02:42 AM - 02:49 AM
Based on the Above Topics-common for CTRT -rt abstracts MO abstracts 02:49 AM - 03:20 AM
HARMONi-2 Trial: Ivonescimab vs. Pembrolizumab in PD-L1+ NSCLC | Phase 3 Results 03:20 AM - 03:27 AM
NVALT-30 Trial (ESMO 2024): Low vs. Standard Dose Pembrolizumab in Stage IV NSCLC | 03:27 AM - 03:34 AM
Pembrolizumab + Chemo in PD-L1 NSCLC | 5-Year Survival Data (Pooled Analysis) 03:34 AM - 03:41 AM
RELATIVITY-104 Trial: Nivolumab + Relatlimab + Chemo vs Nivolumab + Chemo in Stage IV NSCLC 03:41 AM - 03:48 AM
GALAXIES Lung-201 (LBA52): Belrestotug + Dostarlimab in PD-L1 High NSCLC | Interim Phase II Data 03:48 AM - 03:55 AM
TROPION-Lung01 Final OS: Datopotamab Deruxtecan vs Docetaxel in NSCLC | 03:55 AM - 04:02 AM
Akkermansia muciniphila & Multi-Omic Profiling in Advanced NSCLC | ESMO 2024 Abstract 1172O 04:02 AM - 04:09 AM
F. prausnitzii + PD-1 Inhibitors: Boosting Immunotherapy in NSCLC? 04:09 AM - 04:16 AM
Treatment Strategies for Driver-Negative Metastatic NSCLC | 04:16 AM - 04:45 AM

Program Director:

Undiscolosed

Contact Person

Undisclosed

noreply@crsf.in
0000000000

Download

Agenda